Paper Details

  1. Home
  2. Paper Details

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review.

Author: AmaniBahman, AslAkbar Abdollahi, BayazidiYahya, DavariMajid, KadivarMaliheh, MojahedianMahdi, NabizadehAzita, ToroskiMahdi

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Imiglucerase and Eliglustat are both effective treatments for Gaucher's disease type 1, a genetic disorder that affects the liver, spleen, and bone marrow. This review of three studies comparing the two drugs found no significant difference in their efficacy in increasing hemoglobin levels, platelet counts, and reducing liver and spleen size.
Paper Details　
Original Abstract of the Article :
Gaucher's disease (GD) is one of the most common lysosomal diseases in humans. It results from β-glucosidase deficiency and leads to necrosis, especially in macrophages with the accumulation of glucosylceramidase in cells. Most of the deleterious effects of the disease are seen in the liver, spleen,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298139/

データ提供：米国国立医学図書館（NLM）

Navigating Gaucher's Disease: A Comparison of Treatments

Gaucher's disease (GD) is a rare and debilitating lysosomal storage disorder, often leaving individuals feeling like they’re navigating a challenging desert. This research compares the efficacy of two treatments for GD— imiglucerase and eliglustat. The researchers conducted a systematic review of existing studies to evaluate the effectiveness of these treatments in managing GD Type 1. Imagine a camel choosing the best path through a desert, seeking the most effective route to reach its destination—this research helps patients navigate the complex world of GD treatment options.

A Comparative Analysis of Treatment Options

The study found no statistically significant difference in efficacy between imiglucerase and eliglustat in terms of increasing hemoglobin levels, platelet counts, and reducing liver and spleen size. This suggests that both treatments offer comparable benefits for managing GD Type 1.

Finding the Right Path for Gaucher's Disease

This research provides valuable insights for patients and healthcare providers managing GD. While both imiglucerase and eliglustat appear to be effective treatments, individual factors such as side effects and cost may influence treatment choices. Always consult with a healthcare professional to determine the best treatment option for your individual needs.

Dr. Camel's Conclusion

This research offers a valuable comparison of two treatment options for Gaucher’s disease. While both treatments appear effective, the study highlights the importance of considering individual factors when choosing the best path for managing this complex condition.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

30622983

DOI: Digital Object Identifier

PMC6298139

Related Literature

Article Analysis
・Side Effects of eliglustat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.